Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 2/20 | 0.55 |
| ▸ | MMP2 | P08253 | 2/20 | 0.55 |
| ▸ | MMP9 | P14780 | 2/20 | 0.55 |
| ▸ | MMP13 | P45452 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | MMP8 | P22894 | 1/20 | 0.55 |
| ▸ | NR3C1 | P04150 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ITGAV | P06756 | 4/20 | 0.49 |
| ▸ | PGR | P06401 | 4/20 | 0.48 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.48 |
| ▸ | FABP4 | P15090 | 1/20 | 0.48 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5663653 | 1.00 | MMP1 (0.55) | MMP1MMP2MMP9MMP13CA1 | |
| Trifluoroacetic Acid SCHEMBL5663234 | 0.91 | NR3C1 (0.48) | MMP1MMP2MMP9MMP13CA1 | |
| Trifluoroacetic Acid SCHEMBL7394766 | 0.91 | NR3C1 (0.48) | MMP1MMP2MMP9MMP13CA1 | |
| Valine SCHEMBL9352525 | 0.90 | SLC1A3 (0.48) | MMP1MMP2MMP9MMP13CA1 | |
| Valine SCHEMBL9348623 | 0.90 | SLC1A3 (0.48) | MMP1MMP2MMP9MMP13CA1 | |
| SCHEMBL3210497 | 0.83 | KDM4E (0.72) | MMP1MMP2MMP9MMP13CA1 | |
| SCHEMBL31086845 | 0.83 | KDM4E (0.72) | MMP1MMP2MMP9MMP13CA1 | |
| SCHEMBL7066212 | 0.80 | ALDH1A1 (0.65) | MMP1MMP2MMP9MMP13CA1 | |
| SCHEMBL31086960 | 0.80 | ALDH1A1 (0.65) | MMP1MMP2MMP9MMP13CA1 | |
| SCHEMBL5777751 | 0.80 | KDM4E (0.51) | MMP1MMP2MMP9MMP13NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1423152-A4 | SIMULTANEOUS IMAGING OF CARDIAC PERFUSION AND A VITRONECTIN RECEPTOR TARGETED IMAGING AGENT | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2006-12-27 | — | — | EP | claimed |
| CN-1541115-A | Smulaneous imaging of cardiac perfusion and vitronection receptor targeted imaging agent | ����˹�ж�-����˹˹����ҩƷ��˾ | 2004-10-27 | — | — | CN | claimed |
| EP-1423152-A2 | SIMULTANEOUS IMAGING OF CARDIAC PERFUSION AND A VITRONECTIN RECEPTOR TARGETED IMAGING AGENT | Bristol-Myers Squibb Pharma Company (US) | 2004-06-02 | — | — | EP | claimed |
| EP-1307226-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | Bristol-Myers Squibb Pharma Company (US) | 2003-05-07 | — | — | EP | claimed |
| WO-2003013346-A2 | SIMULTANEOUS IMAGING OF CARDIAC PERFUSION AND A VITRONECTIN RECEPTOR TARGETED IMAGING AGENT | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2003-02-20 | — | — | WO | claimed |
| WO-2001097848-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | claimed |
| EP-1140204-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000035492-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | claimed |
| EP-0944619-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | Du Pont Pharmaceuticals Company (US) | 1999-09-29 | — | — | EP | claimed |
| WO-1998023608-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-06-04 | — | — | WO | claimed |
| WO-2024024915-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR PERIOSTIN-MEDIATED DISEASE AND PRURITUS ASSOCIATED THEREWITH | 国立大学法人佐賀大学 | 2024-02-01 | — | — | WO | disclosed |
| CN-1298390-C | Smulaneous imaging of cardiac perfusion and vitronection receptor targeted imaging agent | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2007-02-07 | — | — | CN | disclosed |
| EP-1423152-A4 | SIMULTANEOUS IMAGING OF CARDIAC PERFUSION AND A VITRONECTIN RECEPTOR TARGETED IMAGING AGENT | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2006-12-27 | — | — | EP | disclosed |
| CN-1582166-A | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-02-16 | — | — | CN | disclosed |
| CN-1541115-A | Smulaneous imaging of cardiac perfusion and vitronection receptor targeted imaging agent | ����˹�ж�-����˹˹����ҩƷ��˾ | 2004-10-27 | — | — | CN | disclosed |
| WO-2001097848-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |
| EP-1140204-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035492-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
| EP-0944619-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | Du Pont Pharmaceuticals Company (US) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998023608-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-06-04 | — | — | WO | disclosed |